巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Radius Health

    RDUS
    10.080
    0.000
    0.00%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Radius Health - 延遲價格・最後更新於 14/08 22:00
    最高位
    --
    最低位
    --
    開市價
    --
    前收市價
    10.080
    成交量(千)
    --
    成交額(百萬)
    --
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    480.01
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    23.000 - 4.970
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Radius Health
    證券代碼
    RDUS.US
    所屬板塊
    Drug Manufacturers - Specialty & Generic
    公司業務
    Radius Health Inc is an integrated biopharmaceutical company. It develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company's product, TYMLOS, is for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. The product pipeline of the company includes Abaloparatide-patch for the treatment of postmenopausal women with osteoporosis, Elacestrant, and RAD140. It primarily operates the business in the United States of America and generates key revenue from the sales of TYMLOS.
    發行量
    47342210
    公司總部
    22 Boston Wharf Road, 7th Floor
    公司網址
    https://www.radiuspharm.com
    公司電郵
    ewebb@radiuspharm.com
    公司電話
    +1 617 551-4000
    暫無內容

    關於

    Radius Health(RDUS.US)所屬的行業板塊為Drug Manufacturers - Specialty & Generic。
    Radius Health Inc is an integrated biopharmaceutical company. It develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company's product, TYMLOS, is for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. The product pipeline of the company includes Abaloparatide-patch for the treatment of postmenopausal women with osteoporosis, Elacestrant, and RAD140. It primarily operates the business in the United States of America and generates key revenue from the sales of TYMLOS.
    詳細公司背景可參考: https://www.radiuspharm.com